Travere Therapeutics Inc (NAS:TVTX)
$ 7.23 -0.6 (-7.66%) Market Cap: 550.41 Mil Enterprise Value: 559.06 Mil PE Ratio: 0 PB Ratio: 7.45 GF Score: 58/100

Travere Therapeutics Inc at Bank of America Biotech SMID Cap Conference Transcript

Dec 07, 2022 / 05:15PM GMT
Release Date Price: $20.21 (+0.55%)
Operator

Ladies and gentlemen, the program is about to begin. Reminder that you can submit questions at any time via the Ask Questions tab on the webcast page.

At this time, it is my pleasure to turn the program over to your host, Greg Harrison.

Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Welcome to Bank of America's SMID Biotech Virtual Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, I'm happy to introduce Travere Therapeutics. We have Chris Cline, CFO; and Peter Heerma, Chief Commercial Officer, with us. Thanks for joining, everybody. And for those of you out there watching, if you'd like to send me questions, I'm happy to ask them on your behalf.

Chris, if you'd like to start off with some opening remarks, then we can jump into Q&A.

Christopher Cline
Travere Therapeutics, Inc. - CFO

Sure. Well, first off, thanks Greg and BofA for hosting us. It's great to be here. Peter and I will be making some forward-looking statements. So for full

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot